Request ConsultationPrecision oncology uses genetic and molecular data to create more personalized cancer treatment plans. AI, biomarkers, liquid biopsies, and targeted therapies are helping doctors make cancer care more precise.
Cancer remains a leading global health challenge, with conventional diagnostic and treatment methods often lacking in precision and adaptability. Traditional cancer treatments like chemotherapy and radiation have saved numerous lives, but they do affect healthy cells along with cancerous ones, producing grueling side effects and more underlying health issues.
In the evolving landscape of cancer care, personalized oncology treatment has emerged as a revolutionary aspect. Unlike the traditional one-size-fits-all approach, personalized oncology tailors treatment strategies to the unique genetic, molecular, and clinical characteristics of each patient’s cancer. By leveraging advanced molecular testing, multi-omic analyses, and innovative therapeutic strategies, personalized cancer treatments have the potential to enhance patient outcomes by improving treatment efficacy and minimizing unnecessary side effects.
Cancer treatment is no longer limited to standard protocols. The same drug, given in the same way, may not work for every patient. This is where personalized medicine comes into the picture. It changes the approach. It takes a deeper look at your unique biology, and not just the disease.
What is Precision Oncology?
Precision oncology is an advanced approach to cancer treatment that moves beyond the traditional “one-size-fits-all” model. It tailors therapy to the specific genetic and molecular features of an individual’s tumor. Its core principle is to identify the unique genetic mutations, alterations, or biomarkers driving a cancer’s growth and progression. This personalized strategy aims to improve treatment effectiveness by directly targeting those cancer drivers while also reducing side effects, primarily affecting cancer cells and sparing healthy tissue.
Precision oncology begins with a detailed examination of a patient’s tumor at the molecular level. Known as molecular or genomic profiling, this process identifies genetic alterations specific to the cancer. Modern techniques such as next-generation sequencing (NGS) play a central role by enabling rapid, cost-effective analysis of DNA and RNA. Through whole-genome or whole-transcriptome sequencing, scientists can detect a range of changes, including gene mutations, fusions, and amplifications.
These genetic alterations, or biomarkers, are critical because they offer insight into the tumor’s underlying biology, including its growth and potential to spread. For example, certain gene mutations may reveal vulnerabilities that specific drugs can exploit. Oncologists use the results of this molecular analysis to make informed treatment decisions and pursue highly targeted interventions.
Precision oncology also guides the selection and use of immunotherapies, which harness the body’s immune system to fight cancer. By identifying biomarkers such as programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1), precision oncology can help predict how a patient may respond to certain immune checkpoint inhibitors. Drugs such as pembrolizumab prevent cancer cells from evading the immune system, enabling the body’s defenses to recognize and eliminate them. Chimeric antigen receptor (CAR) T-cell therapy is another form of immunotherapy in which a patient’s own T-cells are engineered to recognize and destroy cancer cells expressing specific antigens.
How Does Precision Oncology Work?
At the core of precision oncology is molecular profiling, which means analyzing the DNA, RNA, and protein expression of a patient’s tumor in order to help identify key biomarkers that are influencing cancer growth and treatment response. The increasing use of molecular profiling in cancer has enabled more precise, data-driven approaches to both treatment selection and clinical trial design.
These insights allow clinicians to:
- Classify tumors not only by location, but by molecular subtype as well.
- Characterize a tumor’s molecular traits or biomarkers to inform diagnosis, prognosis, and therapeutic strategy.
- Leverage the tumor-specific insights to align patients with therapies that target their tumor’s vulnerabilities.
Targeted Therapies and Immunotherapies
Precision oncology directly supports the application of specific treatment modalities, notably targeted therapies and immunotherapies. Targeted therapies are designed to attack cancer cells by focusing on their molecular vulnerabilities identified through precision oncology. These drugs work by blocking specific proteins or pathways that are overactive or mutated in cancer cells, thus inhibiting their growth and spread while simultaneously minimizing damage to healthy cells.
Examples of such drugs include imatinib, which revolutionized chronic myeloid leukemia treatment by inhibiting the BCR-ABL fusion protein. Other examples are trastuzumab, which targets HER2 proteins in breast cancer, and bevacizumab, which attacks the VEGF protein that is found in various types of cancers.
How is it Revolutionizing Cancer Treatment?
Precision oncology is significantly changing cancer care, offering advancements in patient outcomes. By adopting individualized treatment plans, it leads to more effective responses than compared to more generalized therapies. This tailored approach also reduces severe side effects that are associated with traditional chemotherapy, improving the quality of life for many patients.
Precision oncology is also increasingly being integrated into mainstream clinical practices, with ongoing research expanding its reach and effectiveness. While access to precision oncology therapies varies across different geographic and socioeconomic demographics, efforts to make these treatment options more accessible are underway. Ongoing studies are also actively exploring new actionable disease characteristics and refining diagnostic methods, aiming to ensure more patients can benefit from these advanced therapies.
Why Cancer Treatment Is Becoming More Precise
Over the past decade, the definition of precision medicine in cancer care has expanded beyond genomics and targeted therapies to a more holistic approach that considers a patient’s full medical history, comorbidities, socio-economic status, treatment preferences, and access to care.
Cancer treatment is becoming more and more precise due to the increasing understanding of tumor heterogeneity, genetic mutations, treatment resistance, and patient-specific responses. These factors contribute to the complexity of cancer treatment and the need for tailored approaches. Here are some key points:
- Tumor Heterogeneity: Tumors can vary significantly between patients, leading to different responses to treatment. Understanding these differences is crucial for the growth and development of personalized medicine.
- Genetic Mutations: Mutations in key oncogenes and cancer suppressor genes can drive tumor growth and lead to resistance to treatment. Targeting these mutations can help to improve treatment outcomes.
- Treatment Resistance: Tumor heterogeneity can lead to the formation of different cell groups that have distinct molecular characteristics, thus making it challenging to find effective treatments.
- Patient-Specific Response: Each patient's tumor and immune system responds differently to treatment. Tailoring these therapies to individual patient profiles can greatly enhance treatment efficacy and increase chances of success.
The Rise of Biomarker-Driven Cancer Drugs
A cancer biomarker is a measurable biological characteristic. It is a DNA mutation, protein level, immune signal, or other molecular feature that helps classify a cancer, estimate its likely behavior, or predict whether a specific type of treatment is likely to help.
The integration of cancer biomarkers into oncology has revolutionized cancer treatment, bringing remarkable advancements in cancer therapeutics and in the prognosis of cancer patients. The development of personalized medicine represents a turning point in cancer management, as biomarkers help to enable oncologists tailor treatments based on the unique molecular profile of each patient’s tumor.
- HER2: HER2 is a protein encoded by the ERBB2 gene. HER2 status can be assessed using different methods, including immunohistochemistry (IHC) and in situ hybridization techniques. Depending on the cancer and treatment context, reports may describe HER2-positive, HER2-negative, HER2-low, HER2-ultralow, HER2 amplification, or HER2 overexpression. These terms are not necessarily interchangeable, and the clinical significance depends on the cancer type and testing methodology.
- ER and PR: Estrogen receptor (ER) and progesterone receptor (PR) testing are particularly important in diagnosing breast cancer and can help determine whether hormone-directed treatment may have a role. It may provide the percentage of cells expressing the receptor and the intensity of staining, depending on the testing system. As with other biomarkers, the result should be interpreted together with tumor type, stage, HER2 status, and the overall clinical picture.
- EGFR: EGFR inhibitors are targeted cancer therapies that help to block the epidermal growth factor receptor (EGFR), which is a signaling protein that can drive cancer-cell growth. They are particularly important in EGFR-mutated non-small cell lung cancer (NSCLC), where specific genetic alterations can make tumors highly dependent on EGFR signaling.
- KRAS: KRAS, once considered an "undruggable" oncoprotein, is now targetable across multiple mutation subtypes and represents one of the most rapidly evolving areas of precision oncology, spanning non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
How is Liquid Biopsy Is Changing Cancer Testing?
Traditionally, cancer diagnosis has relied largely on imaging, pathological tests, and tissue biopsy, in which a small tumor sample is taken and studied under a microscope or through molecular tests. A liquid biopsy, on the other hand, usually involves testing a blood sample, although other body fluids such as cerebrospinal fluid (CSF), urine, pleural fluid, and saliva may also be tested for cancer-related signals. These may include circulating tumor DNA, circulating tumor cells, cell-free RNA, tumor-derived proteins, or other biomarkers released by cancer cells into the bloodstream.
Liquid biopsy has emerged as a transformative tool in precision oncology, offering a minimally invasive approach for cancer detection, monitoring, and treatment guidance. Unlike traditional tissue biopsies, which are invasive and limited by tumor accessibility and sampling bias, liquid biopsy enables real-time tumor assessment through the analysis of circulating biomarkers in blood and other biofluids.
Liquid biopsy is seen as an important advancement in cancer treatment for the following reasons:
- Minimally invasive: Unlike a traditional tissue biopsy, which may require a surgical or image-guided procedure, a liquid biopsy usually needs only a blood sample. Blood can be drawn within minutes, without surgery or anesthesia, making it easier for patients who are elderly, weak, medically unfit for invasive procedures, or have tumors in difficult-to-reach locations.
- Repeatability: Since it relies on a simple blood draw, a liquid biopsy can be repeated at different stages of treatment. This helps oncologists monitor how the tumor is responding to treatment, detect emerging resistance, and make timely treatment decisions, rather than relying solely on scans that are typically repeated at longer intervals.
- Broader tumor insight: A single-tissue biopsy studies cancer cells from a single selected tumor site. Liquid biopsy may capture genetic material shed into the blood from different tumor areas and, in some cases, from metastatic sites. This can offer a wider view of the cancer’s molecular profile and help guide more personalized treatment planning.
While liquid biopsies have many benefits and applications, it is important to note that they are not a replacement for standard cancer screening or tissue biopsy at present. Tests such as mammography for breast cancer, Pap smear and HPV testing for cervical cancer, colonoscopy or stool-based tests for colorectal cancer, and low-dose CT in selected high-risk individuals for lung cancer still continue to play an important role.
What is the Use of AI in Precision Oncology?
In the era of precision oncology, the integration of artificial intelligence (AI) is not just beneficial; it’s essential. AI enhances our ability to analyze vast amounts of data, allowing for more accurate and tailored treatments. This technology brings clarity to complexity, empowering clinicians to make informed, data-driven decisions that lead to better patient outcomes. Moreover, by identifying patterns that may go unnoticed by the human eye, AI helps us to not only predict cancer progression but also to minimize adverse effects.
AI has also improved the ability to analyze complex molecular data such as genomics, proteomics, and metabolomics to predict how a tumor will respond to different treatments before therapy begins. With this information, the best treatment is selected for therapy for better patient outcomes. Increasingly, some researchers are integrating this technology to monitor therapy over time and inform clinical trial design.
With its ability to detect early-stage cancers, patients are receiving timely intervention that can save lives. Additionally, the technology can reduce treatment toxicity, allowing for a more tailored approach that enhances patients’ quality of life. What is even more impressive is how AI democratizes access to world-class expertise, ensuring that cutting-edge treatment options are available to all.
Targeted Therapies vs Traditional Chemotherapy
Traditional chemotherapy uses powerful drugs to kill rapidly dividing cells throughout the body. It has been the standard cancer treatment for several years and continues to save lives daily. However, chemotherapy doesn’t distinguish between cancer cells and healthy fast-growing cells, which leads to many of its side effects.
On the other hand, chemotherapy drugs travel through your bloodstream, reaching cancer cells located anywhere in your body. These drugs attack cells during division when they are the most vulnerable. Cancer cells divide faster than most normal cells, making them prime targets. The drugs work by damaging cell DNA, preventing cells from dividing, or triggering cell death directly.
Different chemotherapy drugs attack cells at various stages of division. Doctors often combine multiple drugs to help combat cancer cells at different points in their growth cycle. This combination approach increases effectiveness and reduces the chance that cancer cells will become resistant to treatment.
The fundamental difference in both these treatment approaches lies in how they identify their targets. Chemotherapy uses more of a shotgun approach, hitting all rapidly dividing cells. Targeted therapy uses more of a sniper rifle approach, aiming at specific cancer cell features. This precision means targeted therapy causes less collateral damage to healthy tissues. Hair follicles, digestive tract, and bone marrow cells are largely spared because they lack the specific targets these drugs attack.
Challenges in Precision Oncology
While precision oncology continues to evolve rapidly, several challenges remain, particularly when it comes to broader clinical implementation and trial scalability.
One key barrier is the limited availability and adoption of molecular testing across all treatment centers. When testing capabilities vary widely by institution or region, it can hinder consistent patient identification and complicate site selection for biomarker-driven clinical trials. For biotech companies, this can translate into slower enrollment, reduced access to eligible patients, and variability in data quality.
Another challenge is the lack of well-characterized, actionable biomarkers in many tumor types. Although some cancers have established molecular targets, others still lack reliable predictors of response, thus limiting opportunities for targeted therapy development.
What Comes Next for Cancer Care
Personalized Medicine in Oncology is rapidly advancing with novel therapies that enhance specificity and effectiveness. Key breakthroughs include:
- CAR T-cell therapy and Immune Checkpoint Inhibitors: CAR T-cell therapy modifies a patient’s immune cells to better recognize and attack tumors, showing high remission rates in blood cancers like lymphoma and leukemia. Immune checkpoint inhibitors block proteins that suppress immune responses, revitalizing the body’s ability to fight various cancers. More than 15 such inhibitors are FDA-approved, and ongoing trials expand their use to multiple tumor types.
- Personalized Cancer Vaccines and mRNA Technology: New vaccines leverage mRNA to teach the immune system to identify and destroy cancer cells. Trials in several countries focus on cancers including melanoma and colorectal cancer. These vaccines activate immune responses tailored to an individual’s tumor genetics.
- Antibody-Drug Conjugates (ADCs) and Targeted Radiopharmaceuticals: ADCs combine antibodies with potent drugs, directing treatment precisely to cancer cells to minimize toxicity to healthy tissues. Targeted radiopharmaceuticals deliver radiation directly to tumors, enhancing control while sparing normal cells, with innovations like near-infrared photoimmunotherapy showing promise.
- Novel Drug Delivery Systems and AI-Driven Plans: Advanced drug delivery methods, including smart systems combined with wearable sensors, aim to optimize dosing and reduce side effects. AI technologies analyze genetic, proteomic, and clinical data to predict treatment responses, personalize therapy sequences, and support clinical decision-making.
- Late-Phase Clinical Trials Driving Innovation: Numerous global trials investigate these cutting-edge treatments across diverse cancer types, including solid tumors and hematologic malignancies. Trials also explore integrating genomic profiling and functional precision medicine to guide real-time treatment adjustments and improve outcomes.
Together, these innovations form the frontier of Precision Oncology, promising more effective, tailored, and less toxic cancer care. The future of Personalizing cancer care is poised for expansive growth and deeper integration with emerging technologies. As Global cancer burden is projected to rise dramatically, there is an increasing demand for treatments tailored to individual genetic and molecular tumor profiles. This rising burden fuels the expansion of Precision medicine beyond treatment to include early detection and prevention strategies, such as the use of Liquid biopsies and circulating tumor DNA and Cancer Risk Prediction that enable earlier intervention.
Final Thoughts
Technological advances and a broader definition of personalized medicine appear to be reshaping the future of health, potentially making care more targeted, proactive, and tailored to each individual’s needs. As AI, data platforms, and advocacy organizations help to accelerate both research and access, there can be real momentum toward new therapies, early detection, improved patient outcomes, and possibly cures. With continued collaboration across the health ecosystem, the vision of precision medicine as the standard, not the exception, is coming into clearer focus and can help offer new hope for those facing cancer.
Looking forward, precision medicine is set to become the standard in oncology and will be supported by advances in molecular diagnostics, AI integration, and personalized treatment plans.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.